Skip to content

US · MLAB · MEDICAL - EQUIPMENT & SERVICES

Mesa Laboratories, Inc. (MLAB) intrinsic value and stock valuation

$127.93as of 2026-11-21 · Mkt cap 574.25M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Mesa Laboratories, Inc. DCF and intrinsic value

InvestorsCraft values MLAB with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from MLAB’s statements →

Mesa Laboratories, Inc. Graham Number

Graham Number: $30.41d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Equipment & Services Lakewood, CO 80228 mesalabs.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$249.1M+13.2% 5y CAGRd
20122026
Net income
$6.71M+15.5% 5y CAGRd
20122026
Free cash flow
$39.6M+2.4% 5y CAGRd
20122026
Total equity
$186.3M-14.4% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$249.1M$241M$216.2M$219.1M$184.3M
Operating income$18.5M$16.3M-$-272.07M$3.32M$4.7M
Net income$6.71M-$-1.97M-$-254.25M$930K$1.87M
EPSd$1.2M-$-362.8K-$-47.17M$173.5K$350.8K
Operating cash flow$42.8M$46.8M$44.1M$28M$39.2M
Capital expenditure-$-3.25M-$-4.5M-$-2.57M-$-4.54M-$-4.43M
Free cash flow$39.6M$42.3M$41.6M$23.4M$34.8M
Total assets$427.8M$433.4M$446.8M$661.8M$707.4M
Total debt$168.8M$181.5M$231.3M$186.1M$221.1M
Net debt$141.9M$154.2M$203.1M$153.2M$171.8M
Total equity$186.3M$159.8M$145.4M$393.5M$393.8M
Cash and short-term investments$26.9M$27.3M$28.2M$32.9M$49.4M
Income statement
20262025202420232022
Revenue$249.1M$241M$216.2M$219.1M$184.3M
Cost of revenue$90.9M$90.1M$82.9M$85.4M$75.3M
Gross profit$158.3M$150.9M$133.3M$133.7M$109.1M
Research and development expenses$20.3M$19.5M$19.3M$20.5M$15.8M
Selling, general and administrative expenses$119.5M$115M$111.5M$109.9M$88.6M
Other expenses$0.00$0.00$274.5M$0.00$0.00
Operating expenses$139.8M$134.5M$405.3M$130.4M$104.4M
Cost and expenses$230.6M$224.6M$488.3M$215.8M$179.6M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$10.7M$11.9M$5.7M$4.77M$3.88M
Depreciation and amortization$23.3M$24.5M$31.6M$33.1M$25.1M
Ebitda$35.3M$42.4M-$-238.38M$37.5M$32.5M
Operating income$18.5M$16.3M-$-272.07M$3.32M$4.7M
Total other income/expenses, net-$-6.5M-$-10.38M-$-3.57M-$-3.71M-$-1.13M
Income before tax$12M$5.96M-$-275.65M-$-390K$3.57M
Income tax expense$5.3M$7.93M-$-21.4M-$-1.32M$1.7M
Net income$6.71M-$-1.97M-$-254.25M$930K$1.87M
Weighted average shares outstanding$5.51M$5.43M$5.39M$5.32M$5.21M
Weighted average diluted shares outstanding$5.57M$5.43M$5.39M$5.36M$5.33M
Balance sheet
20262025202420232022
Cash and short-term investments$26.9M$27.3M$28.2M$32.9M$49.4M
Net receivables$44.1M$42M$39.1M$42.6M$41.2M
Inventory$26.4M$25.4M$32.7M$34.6M$24.6M
Total current assets$106.3M$102.7M$109.4M$119M$124.3M
Property, plant and equipment, net$48.1M$32.3M$41.4M$28.2M$28.6M
Goodwill and intangible assets$270.2M$278.6M$293.9M$503.3M$541.3M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$321.5M$330.7M$337.4M$542.9M$583.1M
Total assets$427.8M$433.4M$446.8M$661.8M$707.4M
Accounts payable$4.93M$5.75M$6.04M$6.13M$7.9M
Short-term debt$9.31M$104.6M$2.99M$2.87M$2.77M
Deferred revenue$14.7M$14.7M$15.5M$15.7M$14.6M
Total current liabilities$61.9M$164M$44.3M$43.4M$48.1M
Long-term debt$159.5M$76.9M$228.3M$183.3M$218.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$179.6M$109.6M$257.1M$225M$265.5M
Capital lease obligations$17.4M$3.52M$9.6M$2.87M$2.77M
Total liabilities$241.5M$273.5M$301.4M$268.4M$313.6M
Common stock$375.4M$358.5M$343.6M$332.1M$313.5M
Retained earnings-$-185.75M-$-188.94M-$-183.49M$74.2M$76.7M
Accumulated other comprehensive income (loss)-$-3.36M-$-9.78M-$-14.76M-$-12.79M$3.67M
Total equity$186.3M$159.8M$145.4M$393.5M$393.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$168.8M$181.5M$231.3M$186.1M$221.1M
Net debt$141.9M$154.2M$203.1M$153.2M$171.8M
Cash flow statement
20262025202420232022
Net income$6.71M-$-1.97M-$-254.25M$930K$1.87M
Depreciation and amortization$23.3M$24.5M$31.6M$33.1M$25.1M
Stock-based compensation$17.9M$13.1M$11.9M$12.5M$11.4M
Change in working capital-$-4.99M$6.9M$5.97M-$-17.11M-$-7.19M
Accounts receivable-$-3.21M-$-2.92M$4.94M-$-2.12M-$-6.75M
Inventory-$-4.43M$1.15M$2.56M-$-10.18M-$-1.04M
Accounts payable-$-1.2M-$-390K-$-100K-$-1.54M$1.37M
Net cash provided by operating activities$42.8M$46.8M$44.1M$28M$39.2M
Investments in property, plant and equipment-$-3.25M-$-4.25M-$-2.57M-$-4.54M-$-4.43M
Acquisitions, net$0.00$0.00-$-78.74M-$-4.95M-$-300.79M
Net cash used for investing activities-$-3.25M-$-4.5M-$-81.31M-$-9.49M-$-305.23M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-3.52M-$-3.47M-$-3.45M-$-3.41M-$-3.34M
Net cash used for financing activities-$-41.85M-$-44.51M$32.8M-$-33.33M$52.6M
Net change in cash-$-390K-$-890K-$-4.7M-$-16.44M-$-214.52M
Cash at end of period$26.9M$27.3M$28.2M$32.9M$49.4M
Operating cash flow$42.8M$46.8M$44.1M$28M$39.2M
Capital expenditure-$-3.25M-$-4.5M-$-2.57M-$-4.54M-$-4.43M
Free cash flow$39.6M$42.3M$41.6M$23.4M$34.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Mesa Laboratories, Inc.

        Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

        CEO
        Siddhartha C. Kadia
        Employees
        717
        Beta
        0.93

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Mesa Laboratories, Inc. (MLAB)?

        Mesa Laboratories, Inc. (MLAB) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MLAB undervalued?

        MLAB trades at a price of $127.93 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.